Fortress Biotech stock rises after subsidiary’s gout treatment enters Phase 3 trials By Investing.com

Promising New Gout Treatment Advances to Phase 3 Trials: What This Means for Patients Gout, a painful and debilitating form of inflammatory arthritis, affects millions worldwide. Characterized by su...

Understanding Gout and Hyperuricemia

Dotinurad: A Potential New Treatment Option

RUBY and TOPAZ Trials: Evaluating Dotinurad's Effectiveness